WallabyPhenox Risk Report

🛡️ Financial & Liquidity

The company has experienced several financial transactions and changes, indicative of strategic market positioning. Notably, the acquisition of Phenox marks a significant milestone in Wallaby’s financial history. Furthermore, the closure of a major funding round demonstrates solid investor confidence and financial stability.

• Wallaby acquired the German company Phenox for $543 million 🗓 April 22, 2022.
• Wallaby Medical closed a $45 million Series C funding round 🗓 November 26, 2020.

📜 Innovation & R&D

Wallaby/Phenox is notable for its continued commitment to innovation in the medical device field, especially concerning interventional neuroradiology and stroke treatment. The company has been active in enhancing its product offerings and validating their effectiveness through rigorous trials, advancing treatment protocols significantly.

• New coating study results could have a tremendous impact on intracranial aneurysm care 🗓 September 1, 2024.
• One-month coating data suggests the first step towards reducing antiplatelet use in flow-diverter treatments 🗓 June 10, 2025.
• Wallaby/Phenox sets new benchmarks in evidence-based medicine with the PROST trial 🗓 February 5, 2024.
• PROST trial results published, finding PreSet non-inferior to Solitaire in stroke thrombectomy 🗓 January 11, 2024.
• Wallaby/Phenox launched the Pegasus HPC Stent System globally 🗓 September 28, 2022.